基于机器学习的胃癌化疗患者肺部感染风险预测模型构建及验证

注册号:

Registration number:

ChiCTR2600118408 

最近更新日期:

Date of Last Refreshed on:

2026-02-05 09:26:31 

注册时间:

Date of Registration:

2026-02-05 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于机器学习的胃癌化疗患者肺部感染风险预测模型构建及验证

Public title:

Construction and validation of a lung infection risk prediction model for gastric cancer chemotherapy patients based on machine learningConstruction and validation of a lung infection risk prediction model for gastric cancer chemotherapy patients based on machine learning

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于机器学习的胃癌化疗患者肺部感染风险预测模型构建及验证

Scientific title:

Construction and validation of a lung infection risk prediction model for gastric cancer chemotherapy patients based on machine learningConstruction and validation of a lung infection risk prediction model for gastric cancer chemotherapy patients based on machine learning

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郑秋玲 

研究负责人:

陈碧贞 

Applicant:

Qiuling Zheng 

Study leader:

Bizhen Chen 

申请注册联系人电话:

Applicant telephone:

+86 159 8098 0410

研究负责人电话:

Study leader's
telephone:

+86 137 0504 9127

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1147330723@qq.com

研究负责人电子邮件:

Study leader's E-mail:

573073198@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市五四路282号

研究负责人通讯地址:

福建省福州市五四路282号

Applicant address:

282 Wusi Road, Fuzhou, Fujian

Study leader's address:

282 Wusi Road, Fuzhou, Fujian

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建中医药大学附属第二人民医院

Applicant's institution:

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

研究负责人所在单位:

福建中医药大学附属第二人民医院

Affiliation of the Leader:

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SPHFJP-Y2024119-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建中医药大学附属第二人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-20 00:00:00

伦理委员会联系人:

刘莹莹

Contact Name of the ethic committee:

Yingying Liu

伦理委员会联系地址:

福建省福州市鼓楼区五四路282号

Contact Address of the ethic committee:

282 Wusi Road, Fuzhou, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 8780 1705

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建中医药大学附属第二人民医院

Primary sponsor:

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

福建省福州市五四路282号

Primary sponsor's address:

282 Wusi Road, Fuzhou, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建中医药大学附属第二人民医院

具体地址:

福建省福州市五四路282号

Institution
hospital:

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

Address:

282 Wusi Road, Fuzhou, Fujian

经费或物资来源:

Source(s) of funding:

None

研究疾病:

胃恶性肿瘤;感染性并发症  

Target disease:

Gastric cancer;Infection-related complication

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究回顾性调查胃癌化疗患者肺部感染相关危险因素,建立5种基于机器学习算法的胃癌化疗患者肺部感染风险预测模型,通过内部验证比较模型性能,选择最优模型进行前瞻性时间外部验证。旨在提供一个高效准确的预测工具,帮助临床医护人员早期筛查胃癌化疗患者并发肺部感染的高危人群,及时采取防控措施,降低肺部感染发生率。  

Objectives of Study:

This study conducted a retrospective investigation on the risk factors associated with pulmonary infections in patients undergoing chemotherapy for gastric cancer, and established five lung infection risk prediction models based on machine learning algorithms. The performance of the models was compared through internal validation, and the optimal model was selected for prospective time external validation. The aim was to provide an efficient and accurate prediction tool to assist clinical medical staff in early screening of high-risk individuals with concurrent pulmonary infections in patients undergoing gastric cancer chemotherapy, and to promptly implement prevention and control measures to reduce the incidence of pulmonary infections.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.化疗前已发生肺部感染或其他感染性并发症; 2.多脏器功能衰竭、免疫功能缺陷性疾病和血液系统疾病者。 3.临床资料不完整。

Exclusion criteria:

1. Pulmonary infection or other infectious complications occurred before chemotherapy; 2. Patients with multiple organ failure, immunodeficiency diseases and hematological disorders; 3. Incomplete clinical data.

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-03 00:00:00 To 2025-12-16 00:00:00

干预措施:

Interventions:

组别:

建模组

样本量:

256

Group:

Model Construction Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

验模组

样本量:

112

Group:

Model Verification Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建中医药大学附属第二人民医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

联勤保障部队第九〇〇医院 

单位级别:

三甲 

Institution
hospital:

The 900 Hospital of the Joint Logistics Support Force of the People's Liberation Army of China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建 

市(区县):

厦门 

Country:

China

Province:

Fujian

City:

Xiamen

单位(医院):

厦门市中医院 

单位级别:

三甲 

Institution
hospital:

Xiamen Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肺部感染发生的化疗周期

指标类型:

主要指标

Outcome:

The chemotherapy cycles during which lung infections occur

Type:

Primary indicator

测量时间点:

确诊肺部感染时

测量方法:

Measure time point of outcome:

When a confirmed case of lung infection is diagnosed

Measure method:

指标中文名:

体温

指标类型:

次要指标

Outcome:

body temperature

Type:

Secondary indicator

测量时间点:

每次返院化疗时

测量方法:

Measure time point of outcome:

Every time the patient returns to the hospital for chemotherapy

Measure method:

指标中文名:

外周血白细胞计数

指标类型:

次要指标

Outcome:

White blood cell count

Type:

Secondary indicator

测量时间点:

每次返院化疗时

测量方法:

Measure time point of outcome:

Every time the patient returns to the hospital for chemotherapy

Measure method:

指标中文名:

胸部影像学

指标类型:

次要指标

Outcome:

Chest imaging

Type:

Secondary indicator

测量时间点:

每次返院化疗时

测量方法:

胸部CT

Measure time point of outcome:

Every time the patient returns to the hospital for chemotherapy

Measure method:

Chest CT

指标中文名:

肺部感染

指标类型:

主要指标

Outcome:

Pulmonary infection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

模型区分度

指标类型:

主要指标

Outcome:

The discrimination ability of the model

Type:

Primary indicator

测量时间点:

测量方法:

受试者工作特征曲线下面积及其95%CI、准确率、灵敏度、特异度、F-测量值、约登指数

Measure time point of outcome:

Measure method:

The area under the receiver operating characteristic curve, its 95% confidence interval, accuracy rate, sensitivity, specificity, F-measure value, and Youden index

指标中文名:

模型校准度

指标类型:

主要指标

Outcome:

The calibration accuracy of the model

Type:

Primary indicator

测量时间点:

测量方法:

Hosmer-Lemeshow检验、校准曲线、Brier评分

Measure time point of outcome:

Measure method:

Hosmer-Lemeshow test, calibration curve, Brier score

指标中文名:

模型临床实用性

指标类型:

主要指标

Outcome:

The clinical practicability of the model

Type:

Primary indicator

测量时间点:

测量方法:

决策分析曲线

Measure time point of outcome:

Measure method:

Decision curve analysis

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表文章后,若需要原始数据,可联系作者获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publishing the paper, If you need raw data, please contact the author to obtain it.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-05 09:26:11